Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

AIMS: Sacubitril/valsartan is a neprilysin‐inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post‐hoc analysis of a 3‐year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in patients with heart failure and type 2 di...

Descripción completa

Detalles Bibliográficos
Autores principales: Wewer Albrechtsen, Nicolai J., Møller, Andreas, Martinussen, Christoffer, Gluud, Lise L., Rashu, Elias B., Richter, Michael M., Plomgaard, Peter, Goetze, Jens P., Kjeldsen, Sasha, Hansen, Lasse Holst, Gustafsson, Finn, Deacon, Carolyn F., Holst, Jens J., Madsbad, Sten, Bojsen‐Møller, Kirstine N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545540/
https://www.ncbi.nlm.nih.gov/pubmed/35676803
http://dx.doi.org/10.1111/dom.14789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545540/
https://www.ncbi.nlm.nih.gov/pubmed/35676803
http://dx.doi.org/10.1111/dom.14789

Ejemplares similares